Related Experiment Video
Updated: Jul 31, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Mutation screening in juvenile polyposis syndrome
Robert E Pyatt1, Robert Pilarski, Thomas W Prior
1Department of Pathology, Ohio State University, Hamilton Hall 125, 1645 Neil Ave., Columbus, OH 43210, USA.
Insights
Juvenile polyposis syndrome (JPS) genetic testing identified mutations in 30% of patients, primarily in MADH4 and BMPR1A genes. This aids in diagnosing this cancer predisposition syndrome and enables presymptomatic genetic testing.
Area of Science:
- Genetics
- Oncology
- Gastroenterology
Background:
- Juvenile polyposis syndrome (JPS) is an autosomal dominant disorder.
- It is characterized by hamartomatous polyps and increased cancer risk.
- Diagnosis is challenging due to overlapping symptoms with other polyposis syndromes.
Observation:
- This study analyzed 70 unrelated individuals for JPS genetic mutations.
- Sequence analysis of MADH4 and BMPR1A genes was performed.
- Congenital anomalies and cancer status were also assessed.
Findings:
- Germline mutations were found in 30% of JPS cases (11.4% BMPR1A, 18.6% MADH4).
- Most identified mutations were novel, including the first MADH4 splice site alteration.
- No cancer was detected in mutation-positive individuals; only one reported congenital anomaly (pulmonary valve stenosis).
Implications:
- Direct sequence analysis of coding regions and exon-intron boundaries is effective for JPS mutation screening.
- Identifying mutations aids in presymptomatic diagnosis and genetic counseling.
- Understanding mutation types informs diagnostic strategies for JPS.
Abstract:
Juvenile polyposis syndrome (JPS) is an autosomal dominant cancer predisposition syndrome characterized by congenital anomalies, hamartomatous polyps in the gastrointestinal tract, and the development of tumors in these tissues. The diagnosis of JPS is often difficult because of the phenotypic overlap with other hamartomatous polyposis syndromes. Germline mutations have been identified in MADH4 and BMPR1A, aiding in presymptomatic genetic testing. In this study, we describe the results from 3 years of molecular diagnostic screening in JPS. Seventy unrelated individuals referred to our lab for JPS testing were examined through the sequence analysis of coding regions and exon-intron boundaries in both genes. Germline mutations were identified in 30% of cases, with 11.4% in BMPR1A and 18.6% in MADH4. All mutation-positive individuals were negative for cancer at testing, and a single pulmonary valve stenosis was the only congenital anomaly reported. A majority of mutations identified were novel including the first splice site alteration in MADH4. Based on the limited number of exons in each gene, low polymorphism frequency, and high frequency of frameshift or nonsense mutations identified, direct sequence analysis is a suitable methodology for mutation screening if all coding regions and exon-intron boundaries are examined in both genes.
More Related Videos
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023